Navigation Links
Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference

SAN DIEGO, December 6, 2011 /PRNewswire/ --

Speaking today at the plenary session of the IBC's International Antibody Conference in San Diego, Dr. Klaus Schwamborn, CDO of Pepscan Therapeutics, presented Pepscan's protein mimicry platform for the discovery of therapeutic antibodies.

In his presentation 'CLIPS meets GPCRs' Dr. Schwamborn introduced the CLIPS technology and the most recent developments of immunogen design. He showed data demonstrating that Pepscan's synthetic immunogens induce potent antibodies against GPCRs and therefore are able to mimic the native receptor. Resulting antibodies do not only bind strongly to the native receptor, but also show functionality with neutralizing activity in different cell based assays. Pepscan's approach was applied to different targets, supporting the concept of a generic platform for antibody generation for any given GPCR.

Monoclonal antibody therapy is very successful and has major advantages compared to small molecule therapy. However, it is very difficult to generate monoclonal antibodies for certain important drug targets, due to technical constraints, and so far no generic approach has been documented. This is in particular valid for G-protein coupled receptors (GPCR's), for which no FDA approved antibody exists. Over the last years, Pepscan Therapeutics has validated and optimized its CLIPS technology which enables the design and synthesis of conformationally stabilized peptides with a well-defined 3D-structure, resembling the native functional protein surface. New immunogen design strategies were established which allow grafting extracellular domains of any given GPCR onto a synthetic template, mimicking the native receptor structure in an optimal way.

The platform provides a systematic and efficient way of making synthetic immunogens which induce antibodies against the native target. With these immunogens, monoclonal antibodies can be generated by using common antibody technologies, like phage display libraries or hybridoma generation procedures.

Dr. Schwamborn stated: "Our approach has proven to be successful and the fact that we have the possibility to tailor antibodies to certain GPCR domains enables us to engineer antibodies which fulfill certain biological requirements. The immunogen design concept for mimicking extracellular domains of discontinuous epitopes might be also applicable to other important target classes like ion channels".

About Pepscan Therapeutics

Pepscan Therapeutics is a privately held company based in Lelystad, The Netherlands. Pepscan is using its proprietary high throughput CLIPS protein mimicking technology for the development of novel constrained therapeutic peptides and immunogens. Besides its pipeline of proprietary anti-GPCR monoclonal antibody products, Pepscan has various ongoing collaborations with leading pharmaceutical and biotech companies to develop novel therapeutics based on the proprietary CLIPS technology.


CLIPS (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of structurally complex protein domains. CLIPS therapeutic peptides have been shown to exert improved activity and stability. CLIPS peptides are also used as superior immunogens for antibody generation against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins, such as GPCRs. 

SOURCE Pepscan Therapeutics BV
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pepscan Therapeutics Strengthens Management Team
2. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
3. Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing
4. FDA Sets April 24, 2012 as PDUFA Goal Date for Cell Therapeutics Resubmitted Pixantrone New Drug Application
5. Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018
6. Novelos Therapeutics Prices $5.9 Million Public Offering
7. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
8. Antiviral Therapeutics - Technologies, Markets and Companies
9. Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
10. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
11. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may not ... from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there is ... the expense of having to replace NuvaRings more often than necessary. As such, it ...
(Date:11/28/2015)... Aliso Viejo, CA (PRWEB) , ... November 28, 2015 , ... ... 30 new fully customizable media panels to choose from, the possibilities are endless. Users ... angle, and more. With the ProPanel: Pulse masking effects, users are sure to get ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... new study carried out by the University of Toronto and the University of British ... number of hospitalizations for head injuries. The article explains that part of the reason ...
(Date:11/27/2015)... ... , ... A team of Swiss doctors has released a report on mesothelioma ... posted the findings on the website. Click here to read the details now. ... patients who were treated with chemotherapy followed by EPP surgery. Among the 106 patients ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a ... customers 10% off of their purchase of lice treatment product. In addition, customers will ... to a company spokesperson. “Finding lice is a sure way to ruin the holidays, ...
Breaking Medicine News(10 mins):